)
Visual
test
OnKure Therapeutics
OnKure Therapeutics (OKUR) investor relations material
OnKure Therapeutics has been acquired
OnKure Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Advanced clinical pipeline with ongoing PIKture-01 trial for OKI-219 in HR+ and HER2+ metastatic breast cancer, with updated data expected in March 2026.
Next-generation PI3Ka pan-mutant inhibitor candidate for HR+ metastatic breast cancer to be announced in March 2026.
Strategic expansion into vascular malformations, leveraging PI3Ka biology.
Financial highlights
Cash and cash equivalents totaled $59.1 million as of December 31, 2025.
R&D expenses for Q4 2025 were $10.7 million, down from $14.4 million in Q4 2024.
G&A expenses for Q4 2025 were $3.4 million, down from $4.3 million in Q4 2024.
Net loss for Q4 2025 was $13.5 million ($0.99 per share), compared to $17.4 million ($1.37 per share) in Q4 2024.
Net loss for full year 2025 was $59.5 million ($4.40 per share), compared to $52.7 million ($15.28 per share) in 2024.
Outlook and guidance
Updated safety, tolerability, and clinical activity data from PIKture-01 Parts A and B expected in March 2026.
Initial data from triplet expansion arms (Parts C and E) anticipated in 2026.
Next-generation PI3Ka pan-mutant inhibitor candidate announcement and further program details expected in 2026.
Initial Part E triplet data expectations
Pan-mutant inhibitor differentiation strategy
Vascular malformation program development path
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OnKure Therapeutics
- OKI-219 demonstrates high selectivity and tolerability, with key data expected later this year.OKUR
Leerink's Global Healthcare Conference 202526 Dec 2025 - Q1 2026 will bring pivotal OKI-219 data, driving expansion in triplet and pan-mutant programs.OKUREvercore ISI 8th Annual HealthCONx Conference13 Dec 2025
- OKI-219 demonstrates high selectivity and tolerability, with key combination trials ongoing.OKURStifel 2025 Virtual Targeted Oncology Forum25 Nov 2025
- Directors were elected and KPMG was ratified as auditor, with results to be filed with the SEC.OKURAGM 202525 Nov 2025
- OKI-219 shows high selectivity and tolerability, with pivotal data expected in Q1 2026.OKURGuggenheim Securities 2nd Annual Healthcare Innovation Conference17 Nov 2025
- OKI-219 shows strong selectivity and safety, with pivotal breast cancer trial data expected in Q1 2026.OKURStifel 2025 Healthcare Conference17 Nov 2025
- OKI-219 shows promise as a selective PI3Kα inhibitor in breast cancer, with key data due Q1 2026.OKURInvestor Presentation14 Nov 2025
- Advanced clinical programs and strong cash position set stage for key data in early 2026.OKURQ3 20256 Nov 2025
- Q1 2025 net loss was $15.9M, cash $96.7M, and cash runway extends into Q4 2026.OKURQ1 20258 Oct 2025
OnKure Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage